Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.19 USD | +2.62% | -6.68% | -55.11% |
May. 15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.25M | Capitalization | 492M |
---|---|---|---|---|---|
Net income 2024 * | -108M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
Net cash position 2024 * | 254M | Net cash position 2025 * | 173M | EV / Sales 2025 * | 51 x |
P/E ratio 2024 * |
-4.82
x | P/E ratio 2025 * |
-4.57
x | Employees | 119 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.31% |
Latest transcript on Cabaletta Bio, Inc.
1 day | +2.62% | ||
1 week | -6.68% | ||
1 month | -17.89% | ||
3 months | -57.49% | ||
6 months | -36.39% | ||
Current year | -55.11% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
Compliance Officer | - | 19-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-02-18 | |
Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 10.19 | +2.62% | 1,255,752 |
24-05-30 | 9.93 | -1.19% | 731,407 |
24-05-29 | 10.05 | -5.81% | 700,880 |
24-05-28 | 10.67 | -2.29% | 631,618 |
24-05-24 | 10.92 | -2.59% | 506,435 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.11% | 492M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- CABA Stock